Merck, seeking XI factor in race with Bayer, gets FDA fast-track tag for anticoagulant

The FDA has delivered a boost to Merck’s mission to provide a standard-of-care anticoagulation therapy for end-stage renal disease (ESRD) patients by slapping a fast-track tag on midphase asset MK-2060.